Avidity Completes Enrollment in Del-brax Trial's Biomarker Group for Facioscapulohumeral Muscular Dystrophy

Important legal information about the email you will be sending. By using this service, you agree to input your real email address and only send it to people you know. It is a violation of law in some jurisdictions to falsely identify yourself in an email. All information you provide will be used by Fidelity solely for the purpose of sending the email on your behalf. The subject line of the email you send will be "Fidelity.com: "

Avidity Completes Enrollment in Del-brax Trial's Biomarker Group for Facioscapulohumeral Muscular Dystrophy

, MT Newswires - 10:55 AM ET 3/31/2025 default

10:55 AM EDT, 03/31/2025 (MT Newswires) -- Avidity Biosciences ( RNA ) said Monday it completed enrollment in the biomarker group in a phase 1/2 trial of delpacibart braxlosiran, or del-brax, in people with facioscapulohumeral muscular dystrophy, a genetic muscle disorder.

The company said 51 participants were enrolled in the biomarker group.

The del-brax biomarker group was designed for a potential accelerated approval in the US, Avidity said, adding it plans to release a regulatory update in Q2.

The company's shares were down 6% in recent trading.

Price: 29.69, Change: -1.91, Percent Change: -6.04

MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.